Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.01M | 3.00M | 2.45M | 377.00K | 500.00K | 0.00 |
Gross Profit | -35.49M | -3.04M | -3.97M | -3.24M | -85.00K | -23.00K |
EBITDA | -4.63B | 29.67M | -75.74M | -99.41M | -55.90M | -35.81M |
Net Income | 72.88M | 39.79M | -64.17M | -88.98M | -50.35M | -34.33M |
Balance Sheet | ||||||
Total Assets | 43.89M | 30.66M | 33.12M | 53.98M | 86.98M | 19.78M |
Cash, Cash Equivalents and Short-Term Investments | 4.00B | 1.19M | 19.64M | 39.74M | 77.26M | 17.26M |
Total Debt | 9.31B | 31.86M | 48.73M | 36.64M | 0.00 | 14.96M |
Total Liabilities | 12.47M | 37.69M | 57.14M | 43.05M | 7.56M | 20.25M |
Stockholders Equity | 40.79M | -2.50M | -53.83M | -9.68M | 61.67M | 1.90M |
Cash Flow | ||||||
Free Cash Flow | -2.77B | -33.61M | -52.28M | -72.53M | -42.06M | -21.97M |
Operating Cash Flow | -2.77B | -33.55M | -52.04M | -70.98M | -40.59M | -21.91M |
Investing Cash Flow | -24.14M | -16.18M | 758.00K | -4.74M | -3.72M | -55.00K |
Financing Cash Flow | 2.49B | 31.28M | 31.17M | 38.21M | 104.31M | 33.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $11.01M | ― | -335.48% | ― | -12.60% | 95.87% | |
45 Neutral | $9.11M | ― | -193.24% | ― | -66.40% | 65.99% | |
44 Neutral | $8.95M | ― | -69.61% | ― | -11.31% | 47.64% | |
44 Neutral | $16.65M | ― | -63.40% | ― | -91.14% | 9.47% | |
42 Neutral | $10.96M | 0.44 | ― | ― | -73.36% | ― | |
41 Neutral | $10.74M | ― | -235.41% | ― | 0.36% | -17.20% |
On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is a commercial-stage medical diagnostics company focused on cancer prevention, particularly targeting patients with GERD at risk of developing esophageal precancer and cancer. The company utilizes its EsoGuard Esophageal DNA Test, a noninvasive tool designed for early detection of esophageal precancer.
On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.